Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983619 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT00983619 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 136 participants.
The verdict
NCT00983619, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).
Interventions
- DRUG Rituximab
- DRUG MEDI-551
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2010-04-16 |
| Est. Completion | 2019-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983619
The ClinicalTrials.gov registry entry for NCT00983619 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00983619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00983619 about?
NCT00983619 is a clinical study titled "A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies". The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).
What is the current status of trial NCT00983619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2010-04-16. Estimated completion is 2019-03-21.
What interventions are being tested in trial NCT00983619?
The interventions under investigation include: Rituximab (DRUG), MEDI-551 (DRUG).
Who is sponsoring clinical trial NCT00983619?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.